GH vs. VCYT, FTRE, VRDN, RDNT, CSTL, FLGT, STAA, DYN, GERN, and PRVA
Should you be buying Guardant Health stock or one of its competitors? The main competitors of Guardant Health include Veracyte (VCYT), Fortrea (FTRE), Viridian Therapeutics (VRDN), RadNet (RDNT), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), STAAR Surgical (STAA), Dyne Therapeutics (DYN), Geron (GERN), and Privia Health Group (PRVA). These companies are all part of the "medical" sector.
Veracyte (NASDAQ:VCYT) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment.
In the previous week, Veracyte had 12 more articles in the media than Guardant Health. MarketBeat recorded 18 mentions for Veracyte and 6 mentions for Guardant Health. Guardant Health's average media sentiment score of 0.69 beat Veracyte's score of 0.65 indicating that Veracyte is being referred to more favorably in the media.
92.6% of Guardant Health shares are owned by institutional investors. 2.6% of Veracyte shares are owned by company insiders. Comparatively, 6.2% of Guardant Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Veracyte has a net margin of -20.61% compared to Veracyte's net margin of -85.02%. Guardant Health's return on equity of -2.02% beat Veracyte's return on equity.
Veracyte has higher earnings, but lower revenue than Guardant Health. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.
Veracyte currently has a consensus target price of $27.50, suggesting a potential upside of 33.30%. Guardant Health has a consensus target price of $35.78, suggesting a potential upside of 84.04%. Given Veracyte's stronger consensus rating and higher possible upside, analysts clearly believe Guardant Health is more favorable than Veracyte.
Veracyte has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Guardant Health has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.
Veracyte received 167 more outperform votes than Guardant Health when rated by MarketBeat users. Likewise, 72.93% of users gave Veracyte an outperform vote while only 68.75% of users gave Guardant Health an outperform vote.
Summary
Veracyte beats Guardant Health on 11 of the 18 factors compared between the two stocks.
Get Guardant Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Guardant Health Competitors List
Related Companies and Tools
